Raymond James & Associates Buys 129,472 Shares of Sanofi (NASDAQ:SNY)

Raymond James & Associates grew its holdings in shares of Sanofi (NASDAQ:SNY) by 4.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,819,348 shares of the company’s stock after purchasing an additional 129,472 shares during the quarter. Raymond James & Associates owned approximately 0.11% of Sanofi worth $162,479,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SNY. Stablepoint Partners LLC lifted its holdings in shares of Sanofi by 0.8% in the third quarter. Stablepoint Partners LLC now owns 23,893 shares of the company’s stock worth $1,377,000 after buying an additional 189 shares in the last quarter. TCTC Holdings LLC boosted its holdings in Sanofi by 28.0% in the 1st quarter. TCTC Holdings LLC now owns 960 shares of the company’s stock valued at $47,000 after purchasing an additional 210 shares during the period. HB Wealth Management LLC grew its position in shares of Sanofi by 3.7% during the 2nd quarter. HB Wealth Management LLC now owns 6,166 shares of the company’s stock valued at $299,000 after purchasing an additional 221 shares in the last quarter. Insigneo Advisory Services LLC increased its holdings in shares of Sanofi by 3.3% in the second quarter. Insigneo Advisory Services LLC now owns 7,212 shares of the company’s stock worth $371,000 after purchasing an additional 228 shares during the period. Finally, Pinnacle Bancorp Inc. raised its position in shares of Sanofi by 24.6% in the third quarter. Pinnacle Bancorp Inc. now owns 1,227 shares of the company’s stock worth $71,000 after buying an additional 242 shares in the last quarter. 10.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Stock Up 0.1 %

Shares of NASDAQ SNY opened at $54.93 on Friday. The stock has a market capitalization of $139.12 billion, a P/E ratio of 27.60, a PEG ratio of 1.57 and a beta of 0.60. Sanofi has a one year low of $42.63 and a one year high of $58.97. The firm’s 50 day simple moving average is $56.11 and its two-hundred day simple moving average is $51.55. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The company had revenue of $10.75 billion during the quarter, compared to analyst estimates of $16.86 billion. During the same quarter in the previous year, the company posted $0.95 EPS. Sanofi’s revenue for the quarter was up 7.8% on a year-over-year basis. As a group, analysts expect that Sanofi will post 4.26 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on SNY shares. Citigroup upgraded Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Monday, October 14th. Finally, Argus lifted their target price on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Three analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Sanofi currently has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.